With the largest cohort of patients with DNMT3A R882 mutated chronic MNs (MDS, MDS/MPN and MPN) known to date, our multi-institution study set out to address whether DNMT3A R882 mutations confer unique clinicopathologic features in chronic MNs, specifically MDS. Here, DNMT3A is linked to myeloproliferative neoplasm.